|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date07 Mar 1977 |
卡莫司汀缓释植入剂治疗初发恶性脑胶质瘤随机、双盲、安慰剂对照、多中心临床研究
[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical study of carmustine sustained-release implant in the treatment of primary malignant glioma
评价卡莫司汀(BCNU)缓释植入剂治疗初发恶性脑胶质瘤的有效性和安全性。
主要目的: 观察卡莫司汀缓释植入剂(CASANT)治疗初发恶性脑胶质瘤患者的总生存期(OS)。
次要目的:观察卡莫司汀缓释植入剂(CASANT)治疗初发恶性脑胶质瘤患者的无进展生存期(PFS)和安全性。
[Translation] To evaluate the efficacy and safety of carmustine (BCNU) sustained-release implant in the treatment of primary malignant glioma.
Main purpose: To observe the overall survival (OS) of carmustine sustained-release implant (CASANT) in the treatment of patients with primary malignant glioma.
Secondary objective: To observe the progression-free survival (PFS) and safety of carmustine sustained-release implant (CASANT) in the treatment of patients with primary malignant glioma.
卡莫司汀缓释植入剂治疗复发恶性脑胶质瘤随机、双盲、安慰剂对照、多中心临床研究
[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical study of carmustine sustained-release implant in the treatment of recurrent malignant glioma
评价卡莫司汀(BCNU)缓释植入剂治疗复发恶性脑胶质瘤的有效性和安全性。
[Translation] To evaluate the efficacy and safety of carmustine (BCNU) sustained-release implants in the treatment of recurrent malignant glioma.
Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma
The purpose of the study is to determine the safety and efficacy of intracranially implanted Carmustine in the treatment of patients with primary malignant glioma.
100 Clinical Results associated with Shandong Lanjin Pharmaceuticals Co.,Ltd
0 Patents (Medical) associated with Shandong Lanjin Pharmaceuticals Co.,Ltd
100 Deals associated with Shandong Lanjin Pharmaceuticals Co.,Ltd
100 Translational Medicine associated with Shandong Lanjin Pharmaceuticals Co.,Ltd